Drug Patent Watch
DECEMBER 30, 2024
Clinical Pharmacology & Therapeutics , 111(3), 531538. Pharmaceutical Regulations in Japan 2020. Journal of Clinical Pharmacology , 51(3), 531538. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. Freyr Solutions.
pharmaphorum
OCTOBER 18, 2021
A Timeline of COVID-19 Developments in 2020. 7 Petra Doerr, Marie Valentin, Nobumasa Nakashima, Nick Orphanos, Gustavo Santos, Georgios Balkamos & Agnes Saint-Raymond (2021) Reliance: a smarter way of regulating medical products – The IPRP survey, Expert Review of Clinical Pharmacology, 14:2, 173-177. 3, 101 (2020).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Eye on FDA
JANUARY 5, 2022
And speaking of divergent outcomes – one of the most notable occurrences in 2020 was the number of resignations that occurred in the wake of FDA’s decision to approve Aduhelm for Alzheimer’s Disease after an overwhelming committee vote recommending the agency decline to approve. Taking Care of AdComm Vacancies.
RX Note
JANUARY 21, 2023
Adverse Drug Reaction Drug Induced Diseases, 2018 Meyler's Side Effects of Drugs, 2015 Antibiotics The Sanford Guide to Antimicrobial Therapy, 2022 Breastfeeding Briggs' Drugs in Pregnancy and Lactation, 2021 Hale's Medications and Mothers' Milk, 2021 Clinical Practice Applied Therapeutics, 2018 Conn’s Current Therapy, 2022 Current Medical Diagnosis (..)
pharmaphorum
JANUARY 29, 2021
The licensing deal comes as Lilly and partner Pfizer are waiting from a verdict from the FDA on tanezumab as a treatment for pain associated with osteoarthritis, which was supposed to be forthcoming before the end of 2020. While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable.
Pharmacy Joe
JANUARY 10, 2021
In 1989, a study in the Journal of Clinical Pharmacology compared 10, 30, and 90 mg of IM ketorolac with placebo in 126 patients with cancer pain. While all doses were more effective than placebo, there was no difference in effectiveness between 10, 30, or 90 mg of IM ketorolac. 165 patients were split evenly between the 3 groups.
European Pharmaceutical Review
MAY 2, 2023
He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in Medical Sciences Clinical Pharmacology at the University of Glasgow. Dr Mieke Borgs has been Head of Clinical Operations Europe at BeiGene since May 2020.
Expert insights. Personalized for you.
52 
Let's personalize your content